lactic acid has been researched along with pyrazinamide in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (23.08) | 18.7374 |
| 1990's | 2 (15.38) | 18.2507 |
| 2000's | 5 (38.46) | 29.6817 |
| 2010's | 3 (23.08) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Kahn, AM; Weinman, EJ | 1 |
| Besseghir, K; Roch-Ramel, F | 1 |
| Aronson, PS; Guggino, SE | 1 |
| Higashino, K; Moriwaki, Y; Suda, M; Takahashi, S; Yamamoto, T | 1 |
| Gangadharam, PR; Geeta, N; Hsu, YY; Wise, DL | 1 |
| Ain, Q; Garg, SK; Khuller, GK; Sharma, S | 1 |
| Khuller, GK; Sharma, S; Ul-Ain, Q | 1 |
| Khuller, GK; Pandey, R; Prasad, B; Sharma, A; Sharma, S; Zahoor, A | 1 |
| Khuller, GK; Pandey, R; Sharma, S; Zahoor, A | 1 |
| Khuller, GK; Pandey, R | 1 |
| Anzai, N; Nakanishi, T; Ohya, K; Shimada, S; Tamai, I | 1 |
| Attalla, SM; Carter, WG; Christie, D; Elmorsy, E; Fikry, E; Kocon, A; Nwidu, LL; Turner, R; Warren, A | 1 |
1 review(s) available for lactic acid and pyrazinamide
| Article | Year |
|---|---|
Urate transport in the proximal tubule: in vivo and vesicle studies.
Topics: Absorption; Animals; Basement Membrane; Bicarbonates; Biological Transport, Active; Chlorides; Dogs; Humans; Hydroxides; Hydroxyl Radical; Infant, Newborn; Isomerism; Kidney Tubules, Proximal; Lactates; Lactic Acid; Microvilli; Models, Biological; p-Aminohippuric Acid; Probenecid; Pyrazinamide; Rats; Species Specificity; Uric Acid | 1985 |
1 trial(s) available for lactic acid and pyrazinamide
| Article | Year |
|---|---|
Xylitol-induced increase in the concentration of oxypurines and its mechanism.
Topics: Administration, Oral; Adult; Chromatography, High Pressure Liquid; Cytosol; Humans; Hypoxanthine; Hypoxanthines; Infusions, Intravenous; Inosine; Intestine, Small; Lactates; Lactic Acid; Liver; Male; Middle Aged; NAD; Phosphates; Pyrazinamide; Pyruvates; Pyruvic Acid; Saline Solution, Hypertonic; Serum Albumin; Uric Acid; Xanthine; Xanthine Dehydrogenase; Xanthines; Xylitol | 1995 |
11 other study(ies) available for lactic acid and pyrazinamide
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Pyrazinoate transport in the isolated perfused rabbit proximal tubule.
Topics: 4-Acetamido-4'-isothiocyanatostilbene-2,2'-disulfonic Acid; Absorption; Animals; Biological Transport; Epithelium; Ethoxzolamide; Female; In Vitro Techniques; Kidney Tubules, Proximal; Lactates; Lactic Acid; Male; Ouabain; p-Aminohippuric Acid; Pyrazinamide; Rabbits | 1986 |
Paradoxical effects of pyrazinoate and nicotinate on urate transport in dog renal microvillus membranes.
Topics: Animals; Biological Transport, Active; Dogs; Hydrogen-Ion Concentration; Kidney Cortex; Lactates; Lactic Acid; Membranes; Microvilli; Models, Biological; Niacin; Nigericin; Pyrazinamide; Sodium; Uric Acid; Valinomycin | 1985 |
Chemotherapy of tuberculosis in mice using single implants of isoniazid and pyrazinamide.
Topics: Administration, Oral; Analysis of Variance; Animals; Antitubercular Agents; Biocompatible Materials; Biological Availability; Delayed-Action Preparations; Disease Models, Animal; Drug Administration Schedule; Drug Implants; Isoniazid; Lactic Acid; Male; Mice; Mice, Inbred C57BL; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Polymers; Pyrazinamide; Sensitivity and Specificity; Tuberculosis | 1999 |
Role of poly [DL-lactide-co-glycolide] in development of a sustained oral delivery system for antitubercular drug(s).
Topics: Administration, Oral; Animals; Antibiotics, Antitubercular; Antitubercular Agents; Area Under Curve; Biocompatible Materials; Capsules; Delayed-Action Preparations; Drug Compounding; Female; Half-Life; Isoniazid; Lactic Acid; Male; Mice; Particle Size; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Polymers; Pyrazinamide; Rifampin; Solubility | 2002 |
Chemotherapeutic potential of orally administered poly(lactide-co-glycolide) microparticles containing isoniazid, rifampin, and pyrazinamide against experimental tuberculosis.
Topics: Animals; Antibiotics, Antitubercular; Antitubercular Agents; Area Under Curve; Biocompatible Materials; Biological Availability; Capsules; Drug Combinations; Drug Compounding; Isoniazid; Lactic Acid; Mice; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Polymers; Pyrazinamide; Rifampin; Tissue Distribution; Tuberculosis, Pulmonary | 2003 |
Poly (DL-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis.
Topics: Administration, Inhalation; Aerosols; Animals; Antibiotics, Antitubercular; Antitubercular Agents; Area Under Curve; Biological Availability; Chemical and Drug Induced Liver Injury; Chemical Phenomena; Chemistry, Physical; Colony Count, Microbial; Drug Carriers; Drug Combinations; Drug Compounding; Female; Guinea Pigs; Half-Life; Injections, Intravenous; Isoniazid; Lactic Acid; Lung; Male; Microspheres; Mycobacterium tuberculosis; Particle Size; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Polymers; Pyrazinamide; Rifampin; Tuberculosis | 2003 |
Nanoparticle encapsulated antitubercular drugs as a potential oral drug delivery system against murine tuberculosis.
Topics: Administration, Oral; Animals; Antitubercular Agents; Delayed-Action Preparations; Drug Carriers; Drug Compounding; Female; Glycolates; Isoniazid; Lactic Acid; Liver; Lung; Male; Mice; Mycobacterium tuberculosis; Particle Size; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Pyrazinamide; Rifampin; Spleen; Tuberculosis | 2003 |
Subcutaneous nanoparticle-based antitubercular chemotherapy in an experimental model.
Topics: Animals; Antibiotics, Antitubercular; Antitubercular Agents; Biological Availability; Drug Combinations; Drug Compounding; Injections, Subcutaneous; Isoniazid; Lactic Acid; Lung; Mice; Microspheres; Mycobacterium tuberculosis; Particle Size; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Polymers; Pyrazinamide; Rifampin; Spleen; Tissue Distribution; Tuberculosis | 2004 |
Functional cooperation of URAT1 (SLC22A12) and URATv1 (SLC2A9) in renal reabsorption of urate.
Topics: Animals; Benzbromarone; Cells, Cultured; Dogs; Fluorescent Antibody Technique; Glucose Transport Proteins, Facilitative; Humans; Kidney; Lactic Acid; Madin Darby Canine Kidney Cells; Niacin; Oocytes; Organic Anion Transporters; Organic Cation Transport Proteins; Pyrazinamide; Uric Acid; Uricosuric Agents; Vasodilator Agents; Xenopus laevis | 2013 |
Adverse effects of anti-tuberculosis drugs on HepG2 cell bioenergetics.
Topics: Adenosine Triphosphate; Antitubercular Agents; Drug Interactions; Electron Transport Complex I; Electron Transport Complex III; Energy Metabolism; Hep G2 Cells; Humans; Isoniazid; Lactic Acid; Membrane Potential, Mitochondrial; NAD; Pyrazinamide; Rifampin | 2017 |